These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 37941075)

  • 1. Insights gained from single-cell analysis of chimeric antigen receptor T-cell immunotherapy in cancer.
    Tang L; Huang ZP; Mei H; Hu Y
    Mil Med Res; 2023 Nov; 10(1):52. PubMed ID: 37941075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Harnessing the Transcriptional Signatures of CAR-T-Cells and Leukemia/Lymphoma Using Single-Cell Sequencing Technologies.
    Liao YM; Hsu SH; Chiou SS
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress and Pitfalls of Chimeric Antigen Receptor T Cell Immunotherapy against T Cell Malignancies.
    Angelos MG; Patel RP; Ruella M; Barta SK
    Transplant Cell Ther; 2024 Feb; 30(2):171-186. PubMed ID: 37866783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Revolutionizing cancer immunotherapy in solid tumor: CAR engineering and single-cell sequencing insights.
    Pu Z; Wang TB; Mou L
    Front Immunol; 2023; 14():1310285. PubMed ID: 38090577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
    Gauthier J; Yakoub-Agha I
    Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer.
    Gorchakov AA; Kulemzin SV; Kochneva GV; Taranin AV
    Eur Urol; 2020 Mar; 77(3):299-308. PubMed ID: 31471138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer.
    Kandra P; Nandigama R; Eul B; Huber M; Kobold S; Seeger W; Grimminger F; Savai R
    Front Immunol; 2022; 13():903562. PubMed ID: 35720364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update.
    Soundara Rajan T; Gugliandolo A; Bramanti P; Mazzon E
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility.
    Celichowski P; Turi M; Charvátová S; Radhakrishnan D; Feizi N; Chyra Z; Šimíček M; Jelínek T; Bago JR; Hájek R; Hrdinka M
    J Transl Med; 2023 Mar; 21(1):197. PubMed ID: 36922828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
    Kosti P; Maher J; Arnold JN
    Front Immunol; 2018; 9():1104. PubMed ID: 29872437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric antigen receptor (CAR) immunotherapy: basic principles, current advances, and future prospects in neuro-oncology.
    Yoo HJ; Harapan BN
    Immunol Res; 2021 Dec; 69(6):471-486. PubMed ID: 34554405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding CAR T cell-tumor interactions: Paving the way for successful clinical outcomes.
    Korell F; Berger TR; Maus MV
    Med; 2022 Aug; 3(8):538-564. PubMed ID: 35963235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive clinical evaluation of CAR-T cell immunotherapy for solid tumors: a path moving forward or a dead end?
    Drougkas K; Karampinos K; Karavolias I; Koumprentziotis IA; Ploumaki I; Triantafyllou E; Trontzas I; Kotteas E
    J Cancer Res Clin Oncol; 2023 Jun; 149(6):2709-2734. PubMed ID: 36564524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric antigen receptor T-cell therapy for cancer: a basic research-oriented perspective.
    Han C; Kwon BS
    Immunotherapy; 2018 Mar; 10(3):221-234. PubMed ID: 29370727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Applications of single-cell omics for chimeric antigen receptor T cell therapy.
    Ghaffari S; Saleh M; Akbari B; Ramezani F; Mirzaei HR
    Immunology; 2024 Mar; 171(3):339-364. PubMed ID: 38009707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist.
    Maus MV; Levine BL
    Oncologist; 2016 May; 21(5):608-17. PubMed ID: 27009942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical Models in Chimeric Antigen Receptor-Engineered T-Cell Therapy.
    Siegler EL; Wang P
    Hum Gene Ther; 2018 May; 29(5):534-546. PubMed ID: 29390873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utilization of CAR T Cell Therapy in Pediatric Patients.
    Szenes V; Curran KJ
    Semin Oncol Nurs; 2019 Oct; 35(5):150929. PubMed ID: 31526551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical investigation of CAR T cells for solid tumors: Lessons learned and future directions.
    Bagley SJ; O'Rourke DM
    Pharmacol Ther; 2020 Jan; 205():107419. PubMed ID: 31629009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
    Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
    Front Immunol; 2018; 9():1717. PubMed ID: 30108584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.